Published in Gene Therapy Weekly, May 9th, 2002
The novel construct is dubbed iCaspase-9 because of its parentage, which consists of caspase-9 fused to a mutated FKB12 domain, according to J.E. Nor and colleagues, who work at the University of Michigan School of Dentistry and School of Medicine in Ann Arbor, Michigan. The construct works under the control of a drug that triggers its activation.
According to Nor and colleagues, attempts to eradicate angiogenesis in malignant tumors have sometimes failed because redundant survival...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.